Communiqués DSS, Inc.

Actions

DSS

US26253C2017

Emballages papier

Temps Différé NYSE Autres places de cotation 20:59:10 07/07/2026			Varia. 5j.	Varia. 1 janv.
0,6400 ^USD	+2,65 %		+8,47 %	-31,02 %

15/05	DSS, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
08/05	DSS fait état d'un doute sur la continuité d'exploitation dans son rapport annuel 10-K 2025	RE

Communiqués

09/06	DSS, Inc. Withdraws Registration Statement	AQ
08/05	DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing	AQ
15/04	DSS, Inc. Letter to Shareholders	AQ
05/02	DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering	AQ
04/02	DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering	AQ
04/02	DSS, Inc. Announces Launch of Proposed Public Offering	AQ
24/06/25	DSS, Inc.’s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger	AQ
22/05/25	DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth	AQ
24/04/25	Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FINRA Approval to Act as Underwriter and Selling Group Member for Corporate Securities Offerings	AQ
03/02/25	DSS, Inc. Issues Letter to Shareholders	AQ
14/11/24	DSS : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
22/10/24	DSS : Non Reliance of Financial Report Form 8 K	PU
22/10/24	DSS : Amendment to Annual Report Form 10 K/A	PU
16/09/24	DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value	AQ
10/09/24	AmericaFirst Funds Trust Announces Changes to Board of Trustees	AQ
26/08/24	DSS, Inc. Names Jason Grady as Interim Chief Executive Officer	AQ
30/01/24	Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."	AQ
04/01/24	DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market	AQ
22/12/23	DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance Plan	AQ
28/11/23	Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years	AQ
15/11/23	Impact Biomedical Inc. Files Current Report on Form 8-K	AQ
14/11/23	DSS Inc. Wins Patent Dispute with Nichia Corporation	AQ
08/11/23	DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock	AQ
26/10/23	DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule	AQ
23/10/23	DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical	AQ